Given the high physiological relevance of elevated IP-10 expression in inflamed intestinal tissue regions of IBD patients and animal models of experimental colitis [20]–[22], the inhibitory effect on this chemokine may play an important role in the anti-inflammatory effects of the probiotic mixture VSL#3 on inflammatory bowel diseases [9]. Here, CXCL10 is linked to inflammatory bowel disease.